24 weeks ago on Monday, August 21, 2017, I took my first injection of Tremfya (guselkumab) to treat my severe psoriasis. That day I witnessed a solar eclipse as I drove to the dermatology clinic in Sacramento. I recalled the day in grade school (February 26, 1979) when the last total solar eclipse occurred in the Northern Hemisphere. That's around the time when the first psoriasis lesions emerged on my skin. Almost forty years later, would Tremfya finally be the treatment to eclipse the nagging psoriasis all over my skin? A pattern has emerged.
I started my Tremfya (guselkumab) journey on Monday, August 21, 2017. On December 11, after three injections (week 0, 4, 12), I reached that interim endpoint of 16 weeks. Here I evaluate my experience so far with Tremfya, including efficacy, side effects, and how I'm feeling overall. The "verdicts" in this post reflect a moment in time, and certainly are not final.
For much of the last year I looked forward to taking Tremfya (guselkumab) to treat my severe chronic psoriasis. My dermatologist suggested I hold off on the new IL-17A inhibitors until it was FDA approved. Now almost three months into the new treatment I am asking a question I hoped not to need to ask: what’s next?
I wrote this article for the National Psoriasis Foundation as an update to my Treat to Target experience earlier this year. The editor decided to take excerpts from below as a postscript and republish as An ongoing experiment with Treat to Target. See the postscript for a brief week 13 with Tremfya update.
When Monday came I hoped the Tremfya (guselkumab) injection would reverse the reignited psoriasis inflammation. But first I would enjoy, and endure, a long weekend of exciting work including officiating a wedding and baptism, speaking at church, and a hospital visit.